Compare S&P500 ETF (SPY) vs Zimmer Biomet Holdings Inc (ZBH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
S&P500 ETF vs Zimmer Biomet Holdings Inc — how do they compare? S&P500 ETF trades at $778.8 (market cap $821.54B), while Zimmer Biomet Holdings Inc trades at $89.1 (market cap $16.95B). The key difference: S&P500 ETF is far larger — about 48.5× Zimmer Biomet Holdings Inc's market cap, and Zimmer Biomet Holdings Inc pays a 1.08% dividend while S&P500 ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold S&P500 ETF for 205 Days and Zimmer Biomet Holdings Inc for 89 Days on average.
| SPY | ZBH | |
|---|---|---|
Market Cap | $821.54B | $16.95B |
Volume | 40,070,358 | 2,505,240 |
52-Week High | $779.14 | $103.98 |
52-Week Low | $631.99 | $79.58 |
Typical Hold Time | 205 Days | 89 Days |
Sector | — | Health |
Enterprise Value | — | $24.02B |
Dividend Yield | — | 1.08% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SPY (SPDR S&P 500 ETF Trust) trades at $778.18, up 0.12% with a bullish technical signal from moving averages. The ETF shows neutral oscillator readings with RSI at 68.54 suggesting mild overbought conditions. Recent news highlights S&P 500 valuation debates and profit growth expectations of 35% for 2026. Technical support sits at $771 with resistance at $777.
Outlook remains cautiously optimistic given the ETF's broad market exposure, though risks include potential profit growth deceleration to 15% in 2027 and market-wide valuation concerns. The dividend yield of approximately 0.24% provides modest income, while institutional positioning favors large-cap stability amid economic uncertainty.
Zimmer Biomet (ZBH) trades at $88.70, up 0.24% on the day, with a bearish technical outlook but strong fundamental performance. The stock has consistently beaten earnings estimates in recent quarters, with Q2 2026 EPS of $2.07 exceeding expectations. Revenue growth remains steady, reaching $8.23B in 2025, while profitability metrics like a 69.87% gross margin and 9.48% net margin reflect operational efficiency. Recent corporate news includes a $0.24 quarterly dividend declaration and leadership promotions aimed at accelerating commercial transformation.
The investment outlook is mixed, with analyst consensus leaning hold (52.38%) but a price target of $103.11 suggesting 16% upside. Key opportunities include sustained earnings beats and strategic initiatives, while risks involve rising debt levels, competitive pressures, and technical bearish signals. The stock's current valuation at a P/E of 21.57 appears reasonable relative to growth prospects, but investors should weigh fundamental strength against near-term technical weakness and macroeconomic headwinds in the healthcare sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About S&P500 ETF
The ETF is designed to track the performance of the securities and the stocks in the S&P 500 Index. To maintain the composition and weightings, the advisor adjusts the ETF from time to time to conform to periodic changes in the index target.
Read more on SPY →About Zimmer Biomet Holdings Inc
Zimmer Biomet designs, manufactures, and markets orthopedic reconstructive implants, as well as supplies and surgical equipment for orthopedic surgery. With the acquisitions of Centerpulse in 2003 and Biomet in 2015, Zimmer holds the leading share of the reconstructive market in the United States, Europe, and Japan. Roughly 70% of total revenue is derived from sales of large joints, another quarter comes from extremities, trauma, and related surgical products.
Read more on ZBH →
